CURE has also seen modest creation activity over the past month, according to Direxion data.
One leveraged health care ETF that has been a somewhat prolific asset gatherer this year is the ProShares Ultra Nasdaq Biotechnology (NasdaqGM: BIB).
With five biotech ETFs ranking as this year’s top five sector ETFs of any type, it is not surprising that BIB was a $327 million fund at the end of the third quarter and that investors have poured $227.4 million into the ETF this year.
BIB is the double-leveraged equivalent of the iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB), the largest biotech ETF. To its credit, BIB has done fine job of delivering almost exactly double the performance of the NASDAQ Biotechnology Index, IBB’s underlying index. IBB is up 35.6% this year while BIB is higher by 73.2%.
Direxion Daily Healthcare Bull 3x Shares
